ABSTRACT
Group A Streptococcus (Streptococcus pyogenes) (GAS) is the most common bacterial cause of acute pharyngitis, resulting in 20% to 30% of pharyngitis episodes in children and 5% to 15% in adults. 1 Early diagnosis and treatment may result in a shortened course of pharyngitis and also mitigates the risk of sequelae, such as invasive streptococcal disease, peritonsillar abscess formation, streptococcal sepsis or toxic shock syndrome, and rheumatic heart disease.
While most cases of pharyngitis in children and adolescents are caused by viruses and resolve spontaneously, GAS is the most important bacterial cause. As a result, laboratory methods must be directed to rapidly distinguish GAS from the larger group of patients with viral etiologies of pharyngitis, for which antimicrobics are contraindicated. Despite established guidelines for GAS pharyngitis diagnosis and treatment, pediatricians continue to mistreat sore throat in children. 2 The diagnosis of infection relies on clinical presentation without testing or clinical presentation combined with a rapid antigen test and/or culture. Only culture is considered a gold standard, with rapid antigen testing in pediatric patients showing 87% sensitivity (95% confidence interval [CI] , 0.84-0.89) and 96% specificity (95% CI, 0.95-0.97) based on a meta-analysis of data from 1996 and 2013. 3 Rapid antigen tests can be used as the only laboratory method of diagnosis or as a screen with a culture confirmation, which is the recommendation for pediatrics from the American Academy of Pediatrics. 4 This is also the recommendation from the Infectious Diseases Society of America (IDSA) in adults. 5 Because cultures take 24 to 48 hours to complete, the clinician must either treat empirically with antibiotics until the results of the culture are received or wait to treat. Therefore, a test that allows for definitive diagnosis of GAS pharyngitis at the time of the patient visit, without requiring culture confirmation, would provide the best option to ensure appropriate therapy as well as antibiotic stewardship.
Numerous molecular-based GAS tests are now on the market, including the Alere i Strep A test (Alere, Waltham, MA) . In general, the sensitivity and specificity of molecular GAS tests are sufficiently high (>95%) compared with culture, which are summarized in a recent review of molecular diagnostic infectious disease tests. 6 The waived status and the short turnaround time of the Alere i Strep A test make it particularly appropriate for a busy pediatric urgent care setting, in which accurate diagnostic tests and short wait times are paramount. However, the test has not been cleared by the US Food and Drug Administration (FDA) to be used without reflexing negative results to culture. The package insert states, "All negative test results should be confirmed by bacterial culture because negative results do not preclude infection with Group A Streptococcus and should not be used as the sole basis for treatment." 7 As it was our hope to adopt this testing as a definitive diagnostic tool for GAS pharyngitis without need for culture backup, we embarked on a validation of the Alere i Strep A test compared with our current rapid antigen test and culture, with the target population being children seen in outpatient facilities at a single pediatric health care system. The purpose of this article is to report the results of that validation.
Materials and Methods
Over a 2.5-week period (October and early November 2016), 160 children were seen in a single pediatric urgent care center and received testing onsite for GAS pharyngitis. A pediatrician, nurse practitioner, or physician assistant at the urgent care center ordered the test following evaluation of the patient, and specimen collection was performed using a single E-swab placed into Amies liquid media (Floqswab; Copan, Murrietta, CA). Testing was performed by laboratory personnel of the urgent care center laboratory, which carries a certification of accreditation for high-complexity testing.
Testing
The E-swab sample was vortexed for 5 to 10 seconds. The rayon swab from the Alere i strep kit was then dipped into the liquid Amies solution and used for the Alere i Strep A test. A dry swab from the OSOM Strep A test kit (Sekisui Diagnostics, Lexington, MA) was then dipped into the inoculated liquid Amies solution and used to perform the OSOM Strep A test. Finally, a dry swab from the OSOM Strep A test kit was dipped into the liquid Amies solution and then plated onto sheep blood agar and SXT (blood agar with sulfamethoxazole and trimethoprim) agar plates. Cultures were incubated at 37°C in a CO 2 -rich environment (Anaeropack-CO 2 ; MGC, New York, NY) and read 1 day and 2 days following plating. Confirmation of the identification of β-hemolytic streptococci on culture plates was performed using the OSOM Strep A test kit. Only the results of the antigen test, as well as the resulting culture when needed, were provided to the caregiver during this validation period.
Data Analysis
Sensitivity, specificity, positive predictive values, and negative predictive values were calculated using standard methods.
Results
In total, 160 patients were included in the validation study. The patient age ranged from 7.6 months to 17.5 years, with a median age of 6.5 years. The GAS culture was negative in 99 (62%) samples and positive in 61 (38%).
Comparison of Positive Culture and Rapid Tests
Fifty-four (88.5%) of 61 GAS-positive culture samples were also positive using the OSOM Strep A rapid antigen test, with 54 (88.5%) of 61 positive cultures being positive by the rapid antigen test ❚Table 1❚. Sixty (98%) of 61 GAS-positive culture-positive samples were positive using the Alere i Strep A test, while one (1.7%) of the 61 culture-positive samples was negative. This sample had only a single colony of GAS on the plate.
Comparison of Negative Culture and Rapid Tests
Of the 99 samples with negative culture results, nine (9%) were positive using the antigen test. None of these specimens were positive using the Alere i Strep A test (Table 1) . No invalid results were obtained from the Alere i Strep A test for any sample.
Positive and Negative Predictive Values
The positive and negative predictive values for the rapid antigen and Alere i Strep A test are shown in ❚Table 2❚.
Our urgent care laboratory system implemented this testing on February 1, 2017, following validation with culture, as reported above. We compared testing from March and April 2017 using the Alere i molecular strep test with that from March and April 2016, when we used the OSOM Strep A test with reflex to culture. In March and April 2016 alone, we collected 8,648 oropharyngeal specimens across five urgent care centers, with 6,524 (75%) reflexing to culture after a negative strep antigen test. Of those 6,524 cultures, 331 (5%) were positive, which all generated follow-up messages to physicians. One year later, in March and April 2017 alone, we performed 7,695 molecular strep tests across the same five urgent care sites, with only one consistently invalid result requiring backup rapid antigen testing and culture, and thereby we eliminated thousands of cultures from needing to be plated, incubated, and read. All results, except for the one invalid sample, were rapidly available to the ordering physician.
Discussion
In a single pediatric urgent care setting using 160 samples, we validated that the Alere i molecular strep test is 98% sensitive and 100% specific for detecting GAS pharyngitis, with positive and negative predictive values of 100% and 99%, respectively. Several factors may have minimized the discrepancies we observed between the molecular test and culture. First, only a single E-swab was used for the collection of each patient, and the resulting inoculated Amies media were used for all testing, which eliminated the variation that can be seen when two throat swabs are obtained simultaneously from the same patient. Second, even though the Alere i Strep test is waived by the Clinical Laboratory Improvement Amendments (CLIA), all testing in this study was performed by laboratory personnel with medical technologist certification, consistent with the urgent care practices for our institution. This training was also evident in the fact that no "invalid" results were obtained in the study.
In contrast, our study revealed a relatively high false-positive rate (9%) for rapid GAS antigen testing, which demonstrated only 91% specificity and 86% positive predictive value in our hands, compared with culture. This may be due to several factors. The first is the difference in analyte, with a comparison of an antigen assay with a molecular assay and the possibility of antigens expressed by non-GAS bacteria resulting in false-positive results. In addition, there may be the interpretation of the GAS antigen test itself, as the determination of positivity requires the subjective identification of a positive line, and such discrepancies have been demonstrated previously. 8 One last point is that we used E-swabs in this study, and although these swabs are allowed according to the OSOM Strep A package insert, only the dry swab has been reportedly validated by the company. However, our internal validation of the E-swab vs the dry swab for rapid GAS antigen testing suggests that the E-swabs are interchangeable with the dry swabs for this testing (data not shown).
This study is not the first to compare a GAS rapid antigen-based test with a molecular-based test. A recent study by Berry et al 9 compared the Alere i with the instrument-read rapid antigen BD Veritor system (BD, Franklin Lakes, NJ), using swabs from 216 (92.1%) predominantly pediatric patients. Whereas this study similarly showed a high sensitivity of Alere i compared with culture (100%) and a similarly relatively low specificity for the rapid antigen-based test (93.6%), it also demonstrated a lower specificity for the Alere i (91.3%). However, the collection methods in this study used rayon swabs instead of a single E-swab inoculated into liquid Amies, and therefore this In a separate study performed at 10 clinical sites in both adults and children, the Alere i was performed by nonlaboratory personnel, and culture was used as the reference method. 10 Relative to culture, the Alere i demonstrated 96% sensitivity and 94.6% specificity, but these values increased after using a secondary PCR method to adjudicate discrepant results, raising the sensitivity and specificity to 98.7% and 98.5%, respectively.
In addition to the Alere i molecular strep test, several FDA-cleared molecular-based GAS tests are on the market, including the Solana Group A Streptococcus assay (Quidel, San Diego, CA), the Illumigene group A strep DNA amplification assay (Meridian Bioscience, Cincinnati, OH), the Cepheid Xpress Strep A (Cepheid, Sunnyvale, CA), the Cobas Strep A nucleic acid test (Roche Diagnostics, Indianapolis, IN), and the Simplexa Group A Strep (Diasorin Molecular). Of the platforms listed, only the Alere i Strep A test and the Cobas Strep A nucleic acid test are currently CLIA waived, and the Alere i Strep A test has the shortest turnaround time, at less than 10 minutes, with some of the other tests taking up to 1 hour. Uhl and Patel 11 assessed the performance of the Cobas Strep A test by comparing its performance with an in-house GAS PCR assay and reported 100% sensitivity and 98.3% specificity for the Cobas Strep A test. In a multicenter study by Wang et al, 12 the Cobas Strep A test was compared with culture, and they reported 97.7% sensitivity and 93.3% specificity for the assay. Of note, in this study the Cobas Strep A test was performed by nonlaboratory staff.
One consequence of moving from a rapid antigen with a confirmatory culture-based system to a molecular-based system for the diagnosis of GAS pharyngitis is the loss of the ability to grow, identify, and report non-GAS organisms, the most relevant of which are group C Streptococcus (GCS), group G Streptococcus (GGS), and Arcanobacterium haemolyticum. In our urgent cares, when throat cultures were performed as a backup to negative GAS rapid antigen tests, only the presence or absence of GAS colonies was reported, and therefore, this issue was not applicable. However, for those laboratories that currently do report non-GAS colonies from such cultures, this change would likely have low clinical impact, as current IDSA guidelines report that there is no convincing evidence of a clinical response to antibiotic therapy in patients with acute pharyngitis caused by either GCS or GGS. 5 Although A haemolyticum can cause acute pharyngitis, its incidence is relatively low and is usually seen in adolescents and young adults. An additional consequence of moving from a rapid antigen test with reflex to culture to a molecular test is an increase in reagent expense. The Alere i test is listed at $69.50 per test, which far surpasses the combined list price of $4.09 for a single OSOM rapid strep test and reflex culture. Across five of our urgent care sites, which together test about 41,000 specimens per year, this difference in list price reagent costs equates to approximately $2.7 million over the course of a year. However, the list price for the Alere i test is largely inflated over our contracted rate, and therefore the true difference is a fraction of that. In addition, the resulting efficiencies have eliminated our need to perform tens of thousands of GAS cultures each year, our need for an incubator in the laboratory, and well over a thousand follow-up messages to physicians each year. From a full-time employee (FTE) standpoint, this testing saves approximately 6 minutes of technologist time per specimen, which, over five urgent care sites, saves over 4,100 FTE hours per year, equating to approximately $100,400 savings in medical technologist salary, based on 2016 median wages from the US Bureau of Labor Statistics. In addition, reimbursement for the molecular strep test is favorable and therefore offsets some of the large increase in reagent cost.
We note that the current Red Book criteria as well as the most recent IDSA guidelines 4, 5 necessitate the confirmation of negative rapid antigen streptococcal testing in children by backup throat culture. However, there is no current broad consensus on the necessity for such backup after a negative molecular streptococcal test. Despite the manufacturer instructions for the Alere i stating "all negative test results should be confirmed by bacterial culture," we suggest, going forward, based on the test's high sensitivity and specificity, that the Alere i Strep A test can effectively and reliably be used independently in the pediatric population as the sole diagnostic test for the diagnosis of GAS pharyngitis, without culture backup, in the appropriate clinical laboratory setting. Given the test's waived status, this could be especially advantageous to small pediatric clinics that carry a CLIA certificate of waiver, given the extremely small footprint of the instrument, the extraordinarily rapid turnaround time compared with other molecular-based GAS assays, the ease of testing, and the instrument's ability to support other waived testing such as molecular testing for influenza A and B, which are also prevalent in the pediatric population. However, in our study, testing was performed by medical technologists in a high-complexity clinical laboratory, which is potentially different from a waived setting in which the testing could be performed by nonlaboratory personnel. However, previous studies have produced similarly high sensitivity and specificity for molecular strep testing, including with the Alere i, using nonlaboratory personnel, 10 and therefore, with an appropriately sized validation and appropriate training, the adoption of this testing in a waived setting could be similarly successful. 
